FY2025 · ended Dec 31, 2025 · Revenue $212.69M, +1.6% YoY · Filed Feb 27, 2026
Treace Medical Concepts, Inc. (TMCI) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $212.7 million and a net loss of $59.0 million. Free cash flow was -$29.5 million. As of Jun 30, 2026 it held $45.6 million in cash and investments and $72.7 million in total debt.
Revenue (TTM)
$205.31M
-4.0% vs year-ago TTM
Net income (TTM)
$-59.52M
-21.0% vs year-ago TTM
Operating cash flow (TTM)
$-14.58M
+2.2% vs year-ago TTM
Free cash flow (TTM)
$-25.05M
+14.1% vs year-ago TTM
EPS (TTM)
$-0.93
-17.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
64.59M
+3.1% vs prior year
Net cash
$-27.07M
as of Jun 30, 2026
Operating margin
-26.2%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- TMCI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- FL
- Headquarters
- Ponte Vedra, FL
- SEC filer status
- Accelerated filer
- SEC CIK
- 1630627
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $212.7M | $209.4M | $187.1M | $141.8M | $94.4M |
| Operating income | -$54.2M | -$55.7M | -$51.4M | -$34.8M | -$16.5M |
| Net income | -$59.0M | -$55.7M | -$49.5M | -$42.8M | -$20.6M |
| Diluted EPS | -$0.93 | -$0.90 | -$0.81 | -$0.77 | — |
| Operating cash flow | -$16.0M | -$37.2M | -$34.6M | -$30.6M | -$17.2M |
| Free cash flow | -$29.5M | -$48.8M | -$46.0M | -$45.5M | -$19.9M |
| Total assets | $190.6M | $217.1M | $251.9M | $159.0M | $140.8M |
| Total liabilities | $103.2M | $104.2M | $114.0M | $98.5M | $47.7M |
| Stockholders' equity | $87.3M | $112.9M | $137.9M | $60.5M | $93.1M |
| Cash and investments | $48.4M | $75.7M | $123.2M | $81.3M | $105.8M |
| Total debt | $71.9M | $69.7M | $70.3M | $68.6M | $29.4M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 7, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 7, 2026 | Aug 7, 2026 |
| 8-K |
Current report
Shareholder vote results
|
May 20, 2026 | May 19, 2026 |
| 10-Q | Quarterly report | May 8, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 8, 2026 | May 8, 2026 |
| 8-K |
Current report
Results of operations, Officer or director change, Regulation FD disclosure
|
Apr 9, 2026 | Apr 8, 2026 |
All 443 Treace Medical Concepts, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.